Key features and details
- Rat monoclonal [3D09] to VEGF Receptor 2
- Suitable for: WB, IP, Functional Studies
- Reacts with: Mouse
- Isotype: IgG2a
Product nameAnti-VEGF Receptor 2 antibody [3D09]
See all VEGF Receptor 2 primary antibodies
DescriptionRat monoclonal [3D09] to VEGF Receptor 2
SpecificityThis antibody shows no cross-reactivity with VEGF Receptor 1.
Tested applicationsSuitable for: WB, IP, Functional Studiesmore details
Species reactivityReacts with: Mouse
Purified fragment, corresponding to N terminal amino acids 30-200 of Mouse VEGF Receptor 2
- Mouse skin endothelial cells (mSENDs)
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab42230 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent dilution. Predicted molecular weight: 153 kDa.|
|IP||Use at an assay dependent dilution.|
|Functional Studies||Use a concentration of 1 - 5 µg/ml. Can induce VEGF Receptor 2 tyrosine phosphorylation in mouse skin endothelial cells.|
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- CD309 antibody
- CD309 antigen antibody
- EC 184.108.40.206 antibody
ab42230 has been referenced in 1 publication.
- Yu CQ et al. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 49:3870-8 (2008). PubMed: 18487369